KalVista Pharmaceuticals, Inc.
KALVDrugs in Pipeline
4
Phase 3 Programs
2
Upcoming Catalysts
1
Next Catalyst
Q3 2027
Market Overview
Stock performance and key metrics
1 upcoming, 0 past
How KALV's past catalysts played out
KVD900 300 mg
Hereditary Angioedema
KVD900 600 mg
Hereditary Angioedema
KVD001 Injection
Diabetic Macular Edema
KVD900
Hereditary Angioedema
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
KVD900 300 mg | Phase 3 | Hereditary Angioedema | - | - |
KVD900 600 mg | Phase 3 | Hereditary Angioedema | - | - |
KVD001 Injection | Phase 2 | Diabetic Macular Edema | - | - |
KVD900 | Phase 2 | Hereditary Angioedema | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in KalVista Pharmaceuticals, Inc.'s drug pipeline?→
CatalystAlert tracks 4 drug candidates in KalVista Pharmaceuticals, Inc.'s (KALV) pipeline across Phase 3, Phase 2. Its lead program is KVD900 300 mg (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is KalVista Pharmaceuticals, Inc.'s next FDA catalyst?→
KalVista Pharmaceuticals, Inc.'s (KALV) next tracked catalyst is a Phase 3 expected August 31, 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track KALV biotech catalysts?→
Add KALV to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow KalVista Pharmaceuticals, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.